Literature DB >> 30613911

Using Lithium in Older Age Bipolar Disorder: Special Considerations.

Jocelyn Fotso Soh1, Sivan Klil-Drori2, Soham Rej2,3.   

Abstract

Lithium is the gold-standard treatment for bipolar disorder, and is effective in the management of manic, depressive, and maintenance phases of bipolar disorder treatment. Despite this, the implications of lithium use in the older population remain less understood. This critical narrative review aims to better understand the impact of lithium in older age bipolar disorder (OABD), including tolerability and efficacy, based on up-to-date evidence. Relevant studies of efficacy, effectiveness, and tolerability published any time prior to May 2018 were identified using the PubMed keyword search "lithium older adult bipolar disorder" and references from recent international bipolar disorder guidelines. One randomized controlled trial was identified, the GERI-BD (Acute Pharmacotherapy in Late-Life Mania) study. This study found lithium to be effective in late-life mania and hypomania. The remaining literature examining lithium in OABD was reviewed, comprising of a number of small open-label and retrospective studies, with special considerations highlighted. In summary, there is a small yet increasing geriatric evidence base that lithium is effective in OABD. Although there can be adverse effects with lithium, it is generally well tolerated, and there are methods to minimize these risks. Further research would strengthen the evidence base for lithium therapy in OABD. In the meantime, lithium remains the gold-standard treatment for OABD.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30613911     DOI: 10.1007/s40266-018-0628-1

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  79 in total

1.  Mental health service use by elderly patients with bipolar disorder and unipolar major depression.

Authors:  S J Bartels; B Forester; K M Miles; T Joyce
Journal:  Am J Geriatr Psychiatry       Date:  2000       Impact factor: 4.105

2.  Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013.

Authors:  Lakshmi N Yatham; Sidney H Kennedy; Sagar V Parikh; Ayal Schaffer; Serge Beaulieu; Martin Alda; Claire O'Donovan; Glenda Macqueen; Roger S McIntyre; Verinder Sharma; Arun Ravindran; L Trevor Young; Roumen Milev; David J Bond; Benicio N Frey; Benjamin I Goldstein; Beny Lafer; Boris Birmaher; Kyooseob Ha; Willem A Nolen; Michael Berk
Journal:  Bipolar Disord       Date:  2012-12-12       Impact factor: 6.744

3.  Asenapine in the treatment of older adults with bipolar disorder.

Authors:  Martha Sajatovic; Philipp Dines; Edna Fuentes-Casiano; Melanie Athey; Kristin A Cassidy; Johnny Sams; Kathleen Clegg; Joseph Locala; Susan Stagno; Curtis Tatsuoka
Journal:  Int J Geriatr Psychiatry       Date:  2014-10-21       Impact factor: 3.485

4.  Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.

Authors:  Lakshmi N Yatham; Sidney H Kennedy; Sagar V Parikh; Ayal Schaffer; David J Bond; Benicio N Frey; Verinder Sharma; Benjamin I Goldstein; Soham Rej; Serge Beaulieu; Martin Alda; Glenda MacQueen; Roumen V Milev; Arun Ravindran; Claire O'Donovan; Diane McIntosh; Raymond W Lam; Gustavo Vazquez; Flavio Kapczinski; Roger S McIntyre; Jan Kozicky; Shigenobu Kanba; Beny Lafer; Trisha Suppes; Joseph R Calabrese; Eduard Vieta; Gin Malhi; Robert M Post; Michael Berk
Journal:  Bipolar Disord       Date:  2018-03-14       Impact factor: 6.744

5.  The effects of lamotrigine on the pharmacokinetics of lithium.

Authors:  C Chen; L Veronese; Y Yin
Journal:  Br J Clin Pharmacol       Date:  2000-09       Impact factor: 4.335

Review 6.  GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease.

Authors:  Chong Gao; Christian Hölscher; Yueze Liu; Lin Li
Journal:  Rev Neurosci       Date:  2011-12-21       Impact factor: 4.353

7.  Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial.

Authors:  Orestes V Forlenza; Breno S Diniz; Márcia Radanovic; Franklin S Santos; Leda L Talib; Wagner F Gattaz
Journal:  Br J Psychiatry       Date:  2011-05       Impact factor: 9.319

8.  Efficacy of Lurasidone in Adults Aged 55 Years and Older With Bipolar Depression: Post Hoc Analysis of 2 Double-Blind, Placebo-Controlled Studies.

Authors:  Martha Sajatovic; Brent P Forester; Joyce Tsai; Hans Kroger; Andrei Pikalov; Josephine Cucchiaro; Antony Loebel
Journal:  J Clin Psychiatry       Date:  2016-10       Impact factor: 4.384

Review 9.  Consensus statement on the upcoming crisis in geriatric mental health: research agenda for the next 2 decades.

Authors:  D V Jeste; G S Alexopoulos; S J Bartels; J L Cummings; J J Gallo; G L Gottlieb; M C Halpain; B W Palmer; T L Patterson; C F Reynolds; B D Lebowitz
Journal:  Arch Gen Psychiatry       Date:  1999-09

10.  Use of Lithium and Anticonvulsants and the Rate of Chronic Kidney Disease: A Nationwide Population-Based Study.

Authors:  Lars Vedel Kessing; Thomas Alexander Gerds; Bo Feldt-Rasmussen; Per Kragh Andersen; Rasmus W Licht
Journal:  JAMA Psychiatry       Date:  2015-12       Impact factor: 21.596

View more
  1 in total

Review 1.  Evaluation and treatment of older-age bipolar disorder: a narrative review.

Authors:  Rajesh R Tampi; Pallavi Joshi; Gargi Bhattacharya; Sheila Gupta
Journal:  Drugs Context       Date:  2021-05-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.